

Q I P E  
FEB 01 2002

TRANSMITTAL LETTER  
(General - Patent Pending)

Docket No.  
DI-4389 US DIV

In Re Application No. Martis et al.

Serial No.  
09/909,733

Filing Date  
July 20, 2001

Examiner  
D. Lukton

Group Art Unit  
1653

Title:  
IMPROVED PERITONEAL DIALYSIS SOLUTIONS WITH POLYPEPTIDES

RECEIVED

FEB 06 2002

TECH CENTER 1600/2900

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Response to Restriction Requirement; Return Receipt Postcard

in the above identified application.

- No additional fee is required.
- A check in the amount of \_\_\_\_\_ is attached.
- The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. A duplicate copy of this sheet is enclosed.
  - Charge the amount of \_\_\_\_\_
  - Credit any overpayment.
  - Charge any additional fee required.




Signature

Robert M. Barrett (30,142)  
ATTORNEYS FOR APPLICANTS  
Bell, Boyd & Lloyd LLC  
P.O. Box 1135  
Chicago, Illinois 60690-1135

Dated: December 12, 2001

I certify that this document and fee is being deposited on 12/12/2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Signature of Person Mailing Correspondence

Robert J. Buccieri

Typed or Printed Name of Person Mailing Correspondence

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

2/26/02  
RECEIVED

FEB 06 2002

TECH CENTER 1600/2900

Applicant(s): Martis et al.  
Appl. No.: 09/909,733  
Filed: July 20, 2001  
Title: IMPROVED PERITONEAL DIALYSIS SOLUTIONS WITH POLYPEPTIDES  
Art Unit: 1653  
Examiner: D. Lukton  
Docket No.: DI-4389 US DIV

Commissioner for Patents  
Washington, DC 20231

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

In the Claims:

Please cancel Claims 1 and 9-18 without prejudice or disclaimer.

Please add newly-submitted Claims 19-31 as follows:

19. A two part peritoneal dialysis solution designed to be mixed prior to infusion into a patient comprising:

A1  
a first part housed in a first structure including dextrose;  
a second part housed in a second structure including approximately 0.25 to about 4.0% (w/v) polypeptides; and

including in either the first or the second structure a sufficient amount of the following ingredients so when the first part and second part are mixed, the following is provided: 120 to about 150 (mEq/L) sodium; 80.0 to about 110.0 (mEq/L) chloride, 0.0 to about 5.0 (mEq/L)